The next big test is whether using Pluvicto can delay the advancement of prostate cancer enough to delay chemical castration, ...

Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate ...

Detailed data will be presented at a future medical meeting and submitted for regulatory review later this year.

Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer.

Find insight on Novarti, Sanofi and more in the latest Market Talks covering Health Care.

A prostate cancer diagnosis can feel overwhelming, but the growing number of targeted treatments means patients (and their ...

The PSMAddition trial shows 177Lu PSMA-617 significantly delays progression in mHSPC when added to hormone therapy, with a ...

As a leader in its category, Sinotau is probably hoping to follow in the footsteps of Hengrui Pharmaceuticals (1276.HK; ...

Pluvicto is currently approved for metastatic castration-resistant prostate cancer (mCRPC). Given that nearly all mHSPC patients eventually progress to mCRPC, these new data suggest its potential ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

Novartis said Pluvicto demonstrated positive results in patients with PSMA-positive metastatic hormone-sensitive prostate cancer. The Swiss pharmaceutical company on Monday said Pluvicto showed ...